Refusal of shingles vaccine: Implications for public health.
Public Health; Insurance Coverage; Quality-Adjusted Life Years; Cost Benefit Analysis; Neuralgia; Postherpetic – Economics; Postherpetic – Prevention and Control; Treatment Refusal – Statistics and Numerical Data; Viral Vaccines – Economics
Funovits AL; Wagamon KL; Mostow EN; Brodell R T
Journal of the American Academy of Dermatology
2012
2012-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1016/j.jaad.2011.11.931" target="_blank" rel="noreferrer noopener">10.1016/j.jaad.2011.11.931</a>
The Zoster Vaccine Rapidly Loses Effectiveness in Adults Over 60.
Adult; Aged; Incidence; Age Factors; Human; Middle Age; Immunization; Quality-Adjusted Life Years; Nonexperimental Studies; Cost Benefit Analysis; Herpes Zoster Vaccine; Neuralgia; Herpes Zoster – Prevention and Control; Herpes Zoster Vaccine – In Old Age; Postherpetic
The article reports that the Herpes Zoster (HZ) vaccine has decreased its effectiveness in adults that are above 60 years of age. Topics discussed include decline in beneficial effect of the HZ vaccine; determination of an optimal re-dosing strategy to make the vaccine more effective; and decline in the effectiveness of the vaccine in preventing PHN.
Watkins Richard R
Infectious Disease Alert
2016
2016-07
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).